David Slatcher

David Slatcher joined in March 2021 and brings over 30 years of corporate accounting, financial reporting and management experience to Affinivax, including over 15 years in publicly held life sciences companies. Most recently, Mr. Slatcher played a pivotal role in executing the spin-off of Cyclerion Therapeutics, where he served as Corporate Controller and was responsible for building financial systems and business processes. Prior to Cyclerion, Mr. Slatcher served as Corporate Controller at Ironwood Pharmaceuticals, where he had overall responsibility for accounting operations, including commercial collaborations and in-licensing, and was a key participant on several debt and equity financings. Previously, Mr. Slatcher served as the Director of Accounting at Sanofi Pasteur, where he was responsible for financial reporting and administration of the Acambis division, as well as the financial integration after its acquisition. Prior to that Mr. Slatcher had financial leadership roles in early-stage software companies. He began his career in public accounting at Deloitte, where he earned his CPA, and holds a BS in accounting from New York University Stern School of Business.